Related Experiment Video
Updated: Jan 8, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Thrombotic thrombocytopaenic purpura
Manal Yebari1, Aya Elkhlifi1, Douaa Elhmaidi1
1Department of Cardiology, CHU Ibn Sina, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Avenue Ibn Rochd, Agdal, Rabat 10100, Morocco.
Thrombotic thrombocytopaenic purpura (TTP) is a rare but serious adverse effect of clopidogrel, a common antiplatelet medication. Prompt recognition and withdrawal of clopidogrel are crucial for managing TTP and improving patient outcomes.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Thrombotic thrombocytopaenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy.
- Clopidogrel is frequently used post-percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI).
- TTP is a rare but significant adverse effect of clopidogrel therapy.
More Related Videos
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis

